Clinicopathologic and Prognostic Significance of Body Mass Index (BMI) among Breast Cancer Patients in Western China: A Retrospective Multicenter Cohort Based on Western China Clinical Cooperation Group (WCCCG)

Table 3

Clinicopathologic characteristic for postmenopausal patients according to BMI (n=3,932).

Characteristics	BMI (kg/m2) (%)				P
	<18.5	18.5-24.9	≥25	Total
Tumor histology
Carcinoma in situ	10(5.4)	95(3.9)	53(4.1)	158(4.0)	0.59
Invasive carcinoma	165(88.7)	2215(90.6)	1163(89.3)	3543(90.1)
Missing data	11(5.9)	134(5.5)	86(6.6)	231(5.9)
Histologic type
Ductal	145(78.0)	1912(78.2)	997(76.6)	3054(77.7)	0.62
Lobular	4(2.2)	50(2.0)	24(1.8)	78(2.0)
Medullary	1(0.5)	16(0.7)	16(1.2)	33(0.8)
Other	31(16.7)	410(16.8)	230(17.7)	671(17.1)
Missing data	5(2.7)	56(2.3)	35(2.7)	96(2.4)
Nuclear grade
I	9(4.8)	128(5.2)	58(4.5)	195(5.0)	0.52
II	71(38.2)	1015(41.5)	511(39.2)	1597(40.6)
III	30(16.1)	359(14.7)	210(16.1)	599(15.2)
Missing data	76(40.9)	942(38.5)	523(40.2)	1541(39.2)
Lymphovascular-invasion
No	127(68.3)	1495(61.2)	693(53.2)	2315(58.9)	0.02
Yes	1(0.5)	43(1.8)	34(2.6)	78(2.0)
Missing data	58(31.2)	906(37.1)	575(44.2)	1539(39.1)
No. of positive ALN
0	107(57.5)	1184(48.4)	559(42.9)	1850(47.0)	<0.001
1-3	26(14.0)	417(17.1)	191(14.7)	634(16.1)
≥4	44(23.7)	703(28.8)	436(33.5)	1183(30.1)
Missing data	9(4.8)	140(5.7)	116(8.9)	265(6.7)
ER
Negative	70(37.6)	818(33.5)	355(27.3)	1243(31.6)	<0.001
Positive	74(39.8)	1151(47.1)	679(52.2)	1904(48.4)
Missing data	42(22.6)	475(19.4)	268(20.6)	785(20.0)
PR
Negative	83(44.6)	1041(42.6)	461(35.4)	1585(40.3)	<0.001
Positive	61(32.8)	910(37.2)	572(43.9)	1543(39.2)
Missing data	42(22.6)	493(20.2)	269(20.7)	804(20.4)
HER2
Negative	65(34.9)	932(38.1)	539(41.4)	1536(39.1)	0.37
Positive	23(12.4)	258(10.6)	135(10.4)	416(10.6)
Missing data	98(52.7)	1254(51.3)	628(48.2)	1980(50.4)
Tumor Subtypes
Luminal-like	40(21.5)	634(25.9)	403(40.0)	1077(27.4)	0.02
HER2/luminal-like	7(3.8)	106(4.3)	63(4.8)	176(4.5)
HER2-like	16(8.6)	149(6.1)	70(5.4)	235(6.0)
Triple negative	25(13.4)	294(12.0)	134(10.3)	453(11.5)
Missing data	98(52.7)	1261(51.6)	632(48.5)	1991(50.6)
Surgery
Non-surgery	1(0.5)	7(0.3)	11(0.8)	19(0.5)	0.25
MRM	150(80.6)	1973(80.7)	1035(79.5)	3158(80.3)
BCS	12(6.5)	140(5.7)	85(6.5)	237(6.0)
Other	20(10.8)	234(9.6)	112(8.6)	366(9.3)
Missing data	3(1.6)	90(3.7)	59(4.5)	152(3.9)
Chemotherapy
No	51(27.4)	440(18.0)	241(18.5)	732(18.6)	0.005
Yes	127(68.3)	1906(78.0)	1003(77.0)	3036(77.2)
Missing data	8(4.3)	98(4.0)	58(4.5)	164(4.2)
Radiotherapy
No	162(87.1)	2035(83.3)	1021(78.4)	3218(81.8)	<0.001
Yes	15(8.1)	303(12.4)	218(16.7)	536(13.6)
Missing data	9(4.8)	106(4.3)	63(4.8)	178(4.5)
Endocrine therapy
No	142(76.3)	1926(78.8)	945(72.6)	3013(76.6)	<0.001
Yes	35(18.8)	411(16.8)	296(22.7)	742(18.9)
Missing data	9(4.8)	107(4.4)	61(4.7)	177(4.5)

ER, estrogen-receptor; PR, progesterone receptor; ALN, axillary lymph nodes; MRM, modified radical mastectomy; BCS, breast-conserving surgery.
Pearson χ2 test, except Fisher’s exact test.